Cargando…
Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedside
Anti-vascular endothelial growth factor (VEGF) currently used to treat eye diseases have included monoclonal antibodies, antibody fragments, and an aptamer. A different method of achieving VEGF blockade in retinal diseases includes the concept of a cytokine trap. Cytokine traps technology are being...
Autor principal: | Al-Halafi, Ali M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220395/ https://www.ncbi.nlm.nih.gov/pubmed/25378873 http://dx.doi.org/10.4103/0974-620X.142591 |
Ejemplares similares
-
Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice
por: Kim, Il-doo, et al.
Publicado: (2021) -
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
por: Stewart, Michael W
Publicado: (2012) -
The Significance of Neutrophil Extracellular Traps in Colorectal Cancer and Beyond: From Bench to Bedside
por: Li, Dingchang, et al.
Publicado: (2022) -
Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye
por: Michael, Iacovos P, et al.
Publicado: (2014) -
Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy
por: Kanda, Atsuhiro, et al.
Publicado: (2015)